GLSI logo

Greenwich LifeSciences, Inc.

GLSI
Healthcare|Biotechnology|US
$15.17
+0.52 (+3.55%)
DCF Value
$0.13
Tangible Book / Share
$0.21
Cash / Share
$0.61
Next Earnings Report
Nov 13, 2026
EPS est. -$0.30
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (1)

Dec 2031
Est. completion
P3Breast Cancer
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916n=2,250

Recent Press Releases

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Aug 10, 2026 · GlobeNewsWire

SEC Filings (20)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 26, 2026DEFA14AProxy / shareholder voteDocumentIndex
Oct 26, 2026ARSAnnual report to holdersDocumentIndex
Oct 26, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Jun 4, 202610-QQuarterly reportDocumentIndex
Jun 1, 202610-KAnnual reportDocumentIndex
Mar 31, 2026NT 10-KDocumentIndex
Dec 18, 20258-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 3, 2025ARSAnnual report to holdersDocumentIndex
Nov 3, 2025DEFA14AProxy / shareholder voteDocumentIndex
Nov 3, 2025DEF 14AProxy / shareholder voteDocumentIndex
Jul 24, 20258-KMaterial eventDocumentIndex
May 20, 202510-QQuarterly reportDocumentIndex
May 15, 2025NT 10-QDocumentIndex
Apr 15, 202510-KAnnual reportDocumentIndex
Mar 31, 2025NT 10-KDocumentIndex
Dec 20, 2024S-8Employee stock planDocumentIndex
Dec 19, 20248-KMaterial eventDocumentIndex
Nov 14, 202410-QQuarterly reportDocumentIndex